查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2093161

病毒載體生產市場－2026-2032年全球市場預測

Viral Vector Manufacturing Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，病毒載體生產市場將成長至 166.1 億美元，複合年成長率為 17.86%。

主要市場統計數據
基準年 2025 52.5億美元
預計年份：2026年 61.7億美元
預測年份：2032年 166.1億美元
複合年成長率 (%) 17.86%

關於病毒載體生產的執行摘要

病毒載體生產是基因治療、細胞治療、新一代疫苗和先進生物製藥的關鍵基礎。腺結合病毒載體、慢病毒載體、腺病毒載體、逆轉錄病毒載體以及用於精準遞送遺傳物質的新型非複製型可重複性平台的臨床應用不斷擴展，推動了市場對病毒載體的需求。隨著治療產品研發管線從早期開發階段推進到後期階段和商業化生產，製造商優先考慮可擴展的上游製程、穩健的下游製程（用於純化、分析表徵、無菌保證和品管），並確保這些製程符合監管要求。

病毒載體生產產業的變革性變化

病毒載體生產的格局正經歷一場結構性轉變，從小小規模、研究導向生產轉向工業化、閉迴路、數位化驅動的生產模式。早期嚴重依賴貼壁細胞培養和人工操作的工作流程，正被懸浮細胞系統、一次性反應器、自動化填充和精製技術以及更先進的下游純化平台所補充或取代。這些變革提高了生產的可重複性，並更好地控制了污染，並實現了從臨床階段到商業階段更靈活的產能分配。

人工智慧對病毒載體生產的累積影響

人工智慧 (AI) 透過加深對製程的理解、加速研發以及強化品質相關決策，對病毒載體生產產生日益顯著的影響。 AI 驅動的建模能夠分析來自上游製程的複雜資料集，包括細胞增殖、代謝物譜、轉染參數、反應器條件和收穫時間，從而識別出能夠提高生產效率和一致性的製程條件。在下游製程中，機器學習可以透過關聯層析法條件、雜質譜、回收率和效力結果來幫助最佳化純化製程。

病毒載體生產的關鍵區域洞察

亞太地區正崛起為重要的病毒載體生產基地，這主要得益於舉措、日本、韓國、印度、澳洲和新加坡等國生物技術能力的不斷提升、政府主導的生命科學計劃以及活性化的臨床開發活動。該地區受益於先進療法研發方面的投資、完善的GMP基礎設施以及大規模的患者群體，這些都為臨床應用提供了有力支撐。然而，對於在不同國家管理體制下運作的製造商而言，監管協調、人才培養以及高品質原料的穩定供應仍然是至關重要的考量。

東協、海灣合作理事會、歐盟、金磚國家、七國集團和北約的關鍵群體洞察。

東協在病毒載體製造領域發揮日益重要的作用，這得益於新加坡、泰國、馬來西亞、印尼、越南和菲律賓等國擴大藥品生產基地、活性化臨床試驗活動以及支持生物醫學創新。新加坡健全的法規環境和生物製程領域的人才儲備，使該地區成為先進治療藥物研發的門戶，但東協的整體成長取決於區域間合作、人才培養和品質標準的統一。

主要國家病毒載體生產趨勢

美國憑藉其豐富的基因治療研發管線、成熟的GMP基礎設施、豐富的監管經驗以及生物製程領域強大的人才儲備，已成為病毒載體生產的主要中心。加拿大透過其強大的學術研究、臨床網路和不斷擴展的生物製造舉措，為北美生態系統提供支援。墨西哥則憑藉其製藥製造經驗、接近性美國供應鏈的優勢以及對先進醫療保健能力的濃厚興趣，正在開拓新的機會。

病毒載體生產領域領導者使用的實用建議

產業領導者應從病毒載體開發的早期階段就優先考慮可擴展、靈活且以品質為中心的生產策略。製程開發團隊應在設計工作流程時充分考慮商業化準備情況，包括與懸浮培養的兼容性、封閉式製程、標準化原料、經驗證的分析方法以及明確的可比性方案。儘早實施品質源自於設計 (QbD) 可以減少技術轉移過程中的返工，並有助於提交更完善的監管申報文件。

調查方法

本執行摘要基於系統性的二手研究方法，採用公開可查且檢驗的資訊來源，包括監管指南、科學文獻、臨床開發資訊、生產標準、政府生物技術政策、公共衛生機構出版刊物以及經同行評審的病毒載體生產調查方法。本分析著重於已證實的行業促進因素、技術趨勢、監管考慮、區域能力和最佳營運實踐，而不依賴市場規模、市場佔有率或預測。

結論

病毒載體生產正成為一項關鍵能力，它將塑造基因治療、細胞治療和先進生物製藥的未來。該領域正在發展成為一個工業化平台，融合了可擴展的生物製程、密封系統、先進的分析技術、自動化以及嚴格的GMP品管。隨著治療研發管線的日益複雜，卓越的生產能力對於確保產品的一致性、獲得監管部門的認可以及患者及時獲得治療至關重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：病毒載體生產市場：依載體類型分類

  • 腺病毒載體
  • 慢病毒載體
  • 逆轉錄病毒載體
    • γ逆轉錄病毒
    • α逆轉錄病毒
  • 腺結合病毒（AAV）
    • 單鏈AAV
    • 自互補AAV
  • 單純皰疹病毒載體

第8章：病毒載體生產市場：依工作流程分類

  • 下游工藝
    • 細胞株構建
    • 向量設計和克隆
    • 轉染/轉導
  • 上游工藝
    • 純化
    • 集中
    • 配方

第9章：病毒載體生產市場：依給藥途徑分類

  • Ex Vivo
  • In Vivo

第10章：病毒載體生產市場：依企業規模分類

  • 研究規模
  • 臨床前/工藝開發
  • 臨床量表
  • 商業規模

第11章：病毒載體生產市場：依治療領域分類

  • 腫瘤學
  • 罕見遺傳疾病
  • 神經病學
    • 中樞神經系統
    • 周邊神經系統
  • 眼科
  • 免疫學與炎症
  • 感染疾病
  • 心血管系統
  • 代謝/內分泌

第12章：病毒載體生產市場：依應用分類

  • 基因治療
  • 細胞療法
    • 自體療法
    • 同種異體移植療法
  • 疫苗學
  • 研究與開發

第13章：病毒載體生產市場：依最終用戶分類

  • 生技公司
  • 製藥公司
  • 學術和研究機構
    • 學術實驗室
    • 政府附屬實驗室
  • 合約研發生產組織（CDMO）

第14章：病毒載體生產市場：依地區分類

  • 歐洲
  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 中東
  • 非洲

第15章：病毒載體生產市場：依組別分類

  • NATO
  • G7
  • EU
  • BRICS
  • ASEAN
  • GCC

第16章：病毒載體生產市場：依國家分類

  • 美國
  • 中國
  • 德國
  • 日本
  • 英國
  • 印度
  • 法國
  • 加拿大
  • 韓國
  • 義大利
  • 澳洲
  • 巴西
  • 西班牙
  • 俄羅斯
  • 墨西哥

第17章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第18章：公司簡介

  • Thermo Fisher Scientific Inc.
  • Lonza Group
  • Catalent, Inc.
  • Merck KGaA
  • AGC Biologics
  • Charles River Laboratories International, Inc.
  • FUJIFILM Diosynth BIoTechnologies USA, Inc.
  • Wuxi AppTec Co., Ltd.
  • Oxford Biomedica PLC
  • Revvity, Inc.
  • Advanced BioScience Laboratories, Inc.
  • Takara Bio Inc.
  • MaxCyte, Inc.
  • Genezen Laboratories, Inc.
  • Batavia Biosciences BV
  • Biovian Oy
  • Boehringer Ingelheim International GmbH
  • Creative Biogene
  • Danaher Corporation
  • FinVector Oy
  • GE HealthCare Technologies, Inc.
  • Miltenyi BIoTec BV & Co. KG
  • Novartis AG
  • Sanofi SA
  • SK pharmteco Inc.
  • uniQure NV
  • VGXI Inc.
  • Waisman Biomanufacturing
Product Code: MRR-FD3F12D54086

The Viral Vector Manufacturing Market is projected to grow by USD 16.61 billion at a CAGR of 17.86% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.25 billion
Estimated Year [2026] USD 6.17 billion
Forecast Year [2032] USD 16.61 billion
CAGR (%) 17.86%

Viral Vector Manufacturing Executive Summary

Viral vector manufacturing is a critical enabling pillar for gene therapy, cell therapy, next-generation vaccines, and advanced biologics. Demand is being shaped by the clinical expansion of adeno-associated virus vectors, lentiviral vectors, adenoviral vectors, retroviral vectors, and emerging non-replicating and replication-competent platforms used to deliver genetic material with precision. As therapeutic pipelines progress from early development to late-stage and commercial production, manufacturers are prioritizing scalable upstream processing, robust downstream purification, analytical characterization, sterility assurance, and regulatory-ready quality systems.

The sector is defined by high technical complexity. Vector design, producer cell line selection, plasmid quality, transfection efficiency, bioreactor configuration, purification yield, potency testing, and cold-chain logistics all influence product consistency and clinical performance. Regulatory authorities require strong evidence of identity, purity, potency, safety, comparability, and control of adventitious agents, placing manufacturing strategy at the center of development success. In this environment, organizations that integrate process development, quality-by-design, automation, advanced analytics, and compliant documentation are better positioned to reduce batch variability, improve release timelines, and support reliable supply of viral vector-based therapies.

Transformative Shifts in the Viral Vector Manufacturing Landscape

The viral vector manufacturing landscape is undergoing a structural shift from small-scale, research-oriented production toward industrialized, closed, and digitally enabled manufacturing models. Early workflows that relied heavily on adherent cell culture and manual operations are being complemented or replaced by suspension cell systems, single-use bioreactors, automated fill-finish technologies, and intensified downstream purification platforms. These changes support greater reproducibility, improved contamination control, and more flexible capacity deployment across clinical and commercial stages.

Another transformative shift is the rising importance of platform processes. Developers are increasingly seeking modular manufacturing approaches that can be adapted across vector types, indications, and patient populations while maintaining regulatory traceability. The use of stable producer cell lines, optimized plasmid systems, serum-free media, chromatography-based purification, and standardized analytics is helping reduce development friction. At the same time, regulatory expectations for comparability, raw material control, and lifecycle process validation are encouraging earlier alignment between research teams, manufacturing specialists, and quality functions.

Supply-chain resilience has also become a strategic priority. Critical inputs such as GMP-grade plasmids, cell culture media, transfection reagents, chromatography resins, filters, and single-use assemblies require qualified sourcing and contingency planning. The move toward regionalized production networks, dual sourcing, and integrated contract manufacturing relationships reflects the need to reduce disruption risk while supporting geographically diverse clinical trial and patient access requirements.

Cumulative Impact of Artificial Intelligence on Viral Vector Manufacturing

Artificial intelligence is increasingly influencing viral vector manufacturing by improving process understanding, accelerating development, and strengthening quality decision-making. AI-enabled modeling can analyze complex datasets from upstream production, including cell growth, metabolite profiles, transfection parameters, bioreactor conditions, and harvest timing, to identify process conditions associated with higher productivity and consistency. In downstream operations, machine learning can support purification optimization by correlating chromatography conditions, impurity profiles, recovery rates, and potency outcomes.

AI also contributes to analytical development and quality control. Pattern recognition tools can assist with anomaly detection in batch records, environmental monitoring, raw material performance, and in-process testing. Predictive analytics can help anticipate deviations, guide preventive maintenance, and support real-time process monitoring in closed and automated systems. These capabilities are especially relevant because viral vector manufacturing involves biological variability, sensitive product attributes, and complex release testing requirements.

The cumulative impact of artificial intelligence is not the replacement of scientific expertise but the augmentation of process development, technology transfer, and GMP operations. Successful adoption depends on validated data infrastructure, model governance, cybersecurity, explainability, and alignment with regulatory expectations for computerized systems and data integrity. Organizations that combine AI with quality-by-design, process analytical technology, and disciplined knowledge management can improve manufacturing robustness while preserving compliance and scientific accountability.

Key Regional Insights for Viral Vector Manufacturing

Asia-Pacific is advancing as a significant viral vector manufacturing region due to expanding biotechnology capabilities, government-backed life sciences initiatives, and growing clinical development activity in countries such as China, Japan, South Korea, India, Australia, and Singapore. The region benefits from investments in advanced therapy research, increasing GMP infrastructure, and a large patient base that supports clinical translation. However, regulatory harmonization, specialized workforce development, and consistent access to high-quality raw materials remain important considerations for manufacturers operating across diverse national systems.

North America remains a central hub for viral vector manufacturing because of its established biopharmaceutical ecosystem, strong academic and translational research networks, experienced regulatory frameworks, and concentration of advanced therapy clinical trials. The United States, in particular, has deep capabilities in gene therapy process development, GMP viral vector production, analytical testing, and specialized supply chains, while Canada supports the landscape through academic innovation, clinical research infrastructure, and public-private biotechnology initiatives.

Latin America is building relevance through clinical research activity, public health manufacturing experience, and expanding interest in cell and gene therapy infrastructure. Brazil and Mexico are important regional anchors, supported by life sciences capacity and growing regulatory engagement. The region's opportunity lies in developing localized GMP capabilities, strengthening technology transfer pathways, and improving access to advanced therapy manufacturing expertise.

Europe is characterized by strong regulatory oversight, advanced bioprocessing expertise, and a mature clinical research environment. The European Medicines Agency framework, national competent authorities, and established GMP standards support rigorous development of viral vector-based therapies. Countries including Germany, France, the United Kingdom, Italy, and Spain contribute through academic centers, biomanufacturing capacity, and translational medicine networks. Europe's emphasis on quality, traceability, and cross-border clinical collaboration makes it a key region for advanced therapy manufacturing strategies.

The Middle East is increasing its focus on biotechnology, precision medicine, and healthcare diversification, particularly through national strategies in Gulf economies. Regional interest in advanced therapies is creating opportunities for technology partnerships, specialized clinical programs, and future localized manufacturing capabilities. Africa is at an earlier stage in viral vector manufacturing development, but the region's experience with vaccine manufacturing partnerships, public health infrastructure, and emerging biotechnology initiatives provides a foundation for future participation, especially where capacity-building, training, and regulatory strengthening are prioritized.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN is becoming increasingly relevant to viral vector manufacturing through its expanding pharmaceutical production base, rising clinical trial activity, and policy support for biomedical innovation in countries such as Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines. Singapore's strong regulatory environment and bioprocessing talent base help position the group as a gateway for advanced therapy development, while broader ASEAN growth depends on regional collaboration, workforce training, and harmonized quality standards.

The GCC is advancing biotechnology and precision medicine through healthcare diversification strategies, investment in research infrastructure, and partnerships aimed at building specialized manufacturing and clinical capabilities. While viral vector manufacturing in the GCC remains developing, the group's emphasis on genomic medicine, rare disease programs, and high-standard healthcare delivery creates a pathway for future adoption of advanced therapy production and supply-chain localization.

The European Union provides one of the most structured regulatory environments for viral vector manufacturing, supported by harmonized advanced therapy medicinal product requirements, GMP expectations, and coordinated scientific assessment mechanisms. EU member states contribute extensive bioprocessing knowledge, academic-industry collaboration, and cross-border clinical research networks, making the group central to quality-driven development and regulatory alignment for viral vector-based therapies.

BRICS countries represent a diverse and strategically important group for viral vector manufacturing. China and India are expanding biomanufacturing capabilities and scientific output, Brazil contributes regional public health and biologics expertise, Russia maintains biomedical research capacity, and South Africa offers a platform for broader African life sciences development. The group's relevance is tied to domestic innovation policies, large patient populations, manufacturing scale-up ambitions, and the need for consistent GMP maturity across markets.

The G7 remains highly influential due to advanced regulatory systems, significant biomedical research intensity, established pharmaceutical manufacturing infrastructure, and leadership in clinical translation of gene and cell therapies. The United States, Canada, Japan, Germany, France, Italy, and the United Kingdom collectively shape quality expectations, analytical standards, technology adoption, and policy discussions affecting viral vector manufacturing.

NATO countries are not a commercial market category, but many member states maintain advanced biomedical manufacturing, public health preparedness, and biotechnology security capabilities. Within this group, viral vector manufacturing intersects with resilient supply chains, medical countermeasure readiness, advanced therapy access, and secure manufacturing infrastructure. Collaboration among member countries can support workforce development, quality standardization, and continuity of supply for critical biologics technologies.

Key Country Insights for Viral Vector Manufacturing

The United States is the leading operational center for viral vector manufacturing due to its extensive gene therapy pipeline, mature GMP infrastructure, regulatory experience, and deep base of bioprocessing talent. Canada supports the North American ecosystem with strong academic research, clinical networks, and growing biomanufacturing initiatives. Mexico is developing opportunities through pharmaceutical manufacturing experience, proximity to U.S. supply chains, and interest in advanced healthcare capabilities.

Brazil is the most prominent Latin American country for viral vector manufacturing potential, supported by biologics expertise, public health institutions, and expanding biotechnology initiatives. In Europe, the United Kingdom has strong translational medicine capabilities, advanced therapy clinical activity, and specialized manufacturing knowledge. Germany contributes through engineering excellence, bioprocessing depth, and a strong life sciences base, while France combines biomedical research, public investment in biomanufacturing, and regulatory expertise. Russia maintains scientific and biomedical research capacity, though international collaboration and supply-chain access can influence manufacturing progress. Italy and Spain contribute through clinical research networks, hospital-based advanced therapy programs, and growing biotechnology ecosystems.

China is rapidly expanding viral vector manufacturing capabilities through large-scale biotechnology investment, gene therapy development activity, and increasingly sophisticated GMP infrastructure. India offers strong potential through its pharmaceutical manufacturing base, skilled scientific workforce, and expanding biologics capabilities, though specialized viral vector scale-up and regulatory harmonization remain important areas of development. Japan is highly relevant due to its regenerative medicine framework, quality-focused manufacturing culture, and advanced clinical research environment.

Australia contributes through strong clinical trial infrastructure, academic research, and regulatory credibility, making it a valuable location for early-stage advanced therapy development and regional collaboration. South Korea is strengthening its role through biomanufacturing investment, advanced healthcare infrastructure, and national support for biotechnology, with growing capabilities in cell and gene therapy manufacturing, analytical development, and GMP operations.

Actionable Recommendations for Viral Vector Manufacturing Leaders

Industry leaders should prioritize scalable, flexible, and quality-centered manufacturing strategies from the earliest stages of viral vector development. Process development teams should design workflows with commercial readiness in mind, including suspension culture compatibility, closed processing, standardized raw materials, validated analytics, and defined comparability protocols. Early quality-by-design implementation can reduce rework during technology transfer and support stronger regulatory submissions.

Organizations should strengthen raw material governance by qualifying suppliers, mapping critical inputs, establishing dual-source strategies where feasible, and maintaining transparent documentation for plasmids, media, reagents, filters, and single-use systems. Investment in analytical capability is equally important, especially for potency assays, full-empty capsid analysis, residual impurity detection, replication-competent virus testing, and genomic integrity assessment.

Leaders should adopt automation, process analytical technology, and AI-enabled monitoring in a controlled and validated manner. Digital batch records, real-time deviation detection, and integrated manufacturing execution systems can improve data integrity and operational consistency. Workforce development is also essential, as viral vector manufacturing requires expertise across virology, molecular biology, cell culture, purification science, GMP quality systems, regulatory affairs, and aseptic operations.

Strategic partnerships should be evaluated not only on capacity but also on technical depth, regulatory track record, analytical maturity, and technology transfer discipline. Organizations that build resilient regional supply networks, invest in platform manufacturing, and align clinical development with manufacturing readiness can reduce execution risk and improve therapy availability.

Research Methodology

This executive summary is based on a structured secondary research methodology using publicly available and verifiable sources, including regulatory guidance, scientific literature, clinical development information, manufacturing standards, government biotechnology policies, public health agency publications, and peer-reviewed research on viral vector production. The analysis emphasizes validated industry drivers, technology trends, regulatory considerations, regional capabilities, and operational best practices without relying on market sizing, market share, or forecasting.

The research approach includes cross-verification of technical insights related to vector platforms, upstream and downstream processing, analytical testing, GMP compliance, and supply-chain requirements. Regional, group, and country insights are synthesized from observable biotechnology infrastructure, regulatory maturity, clinical research activity, and advanced therapy policy environments. The methodology prioritizes accuracy, traceability, and relevance for decision-makers in gene therapy manufacturing, cell therapy manufacturing, vaccine vector production, and advanced biologics operations.

Conclusion

Viral vector manufacturing is becoming a defining capability for the future of gene therapy, cell therapy, and advanced biologics. The field is moving toward industrialized platforms that combine scalable bioprocessing, closed systems, advanced analytics, automation, and rigorous GMP quality controls. As therapeutic pipelines become more complex, manufacturing excellence will be essential for ensuring product consistency, regulatory confidence, and timely patient access.

Regional and national ecosystems are evolving at different speeds, with North America, Europe, and leading Asia-Pacific countries providing strong foundations while emerging regions build specialized capacity through investment, partnerships, and policy support. Artificial intelligence, process analytical technology, and digital quality systems are expected to strengthen decision-making and operational resilience when implemented with validated controls.

For industry leaders, the central imperative is clear: viral vector manufacturing must be treated as a strategic asset, not a downstream operational function. Organizations that invest early in robust process design, analytical science, supplier resilience, workforce capability, and compliant digital infrastructure will be better positioned to support the next generation of viral vector-based therapies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Viral Vector Manufacturing Market, by Vector Type

  • 7.1. Introduction
  • 7.2. Adenoviral Vectors
  • 7.3. Lentiviral Vectors
  • 7.4. Retrovirus Vectors
    • 7.4.1. Gamma-retrovirus
    • 7.4.2. Alpha-retrovirus
  • 7.5. Adeno-Associated Virus (AAV)
    • 7.5.1. Single-Stranded AAV
    • 7.5.2. Self-Complementary AAV
  • 7.6. Herpes Simplex Vectors

8. Viral Vector Manufacturing Market, by Workflow

  • 8.1. Introduction
  • 8.2. Downstream Processing
    • 8.2.1. Cell Line Development
    • 8.2.2. Vector Design & Cloning
    • 8.2.3. Transfection/Transduction
  • 8.3. Upstream Processing
    • 8.3.1. Purification
    • 8.3.2. Concentration
    • 8.3.3. Formulation

9. Viral Vector Manufacturing Market, by Delivery Method

  • 9.1. Introduction
  • 9.2. Ex Vivo
  • 9.3. In Vivo

10. Viral Vector Manufacturing Market, by Scale of Operation

  • 10.1. Introduction
  • 10.2. Research-Scale
  • 10.3. Preclinical/Process Development
  • 10.4. Clinical-Scale
  • 10.5. Commercial-Scale

11. Viral Vector Manufacturing Market, by Therapeutic Area

  • 11.1. Introduction
  • 11.2. Oncology
  • 11.3. Rare Genetic Disorders
  • 11.4. Neurology
    • 11.4.1. Central Nervous System
    • 11.4.2. Peripheral Nervous System
  • 11.5. Ophthalmology
  • 11.6. Immunology & Inflammation
  • 11.7. Infectious Diseases
  • 11.8. Cardiovascular
  • 11.9. Metabolic & Endocrine

12. Viral Vector Manufacturing Market, by Application

  • 12.1. Introduction
  • 12.2. Gene Therapy
  • 12.3. Cell Therapy
    • 12.3.1. Autologous Therapies
    • 12.3.2. Allogeneic Therapies
  • 12.4. Vaccinology
  • 12.5. Research & Development

13. Viral Vector Manufacturing Market, by End User

  • 13.1. Introduction
  • 13.2. Biotechnology Companies
  • 13.3. Pharmaceutical Companies
  • 13.4. Academic & Research Organizations
    • 13.4.1. Academic Laboratories
    • 13.4.2. Government Labs
  • 13.5. Contract Development & Manufacturing Organizations

14. Viral Vector Manufacturing Market, by Region

  • 14.1. Europe
  • 14.2. Asia-Pacific
  • 14.3. North America
  • 14.4. Latin America
  • 14.5. Middle East
  • 14.6. Africa

15. Viral Vector Manufacturing Market, by Group

  • 15.1. NATO
  • 15.2. G7
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. ASEAN
  • 15.6. GCC

16. Viral Vector Manufacturing Market, by Country

  • 16.1. United States
  • 16.2. China
  • 16.3. Germany
  • 16.4. Japan
  • 16.5. United Kingdom
  • 16.6. India
  • 16.7. France
  • 16.8. Canada
  • 16.9. South Korea
  • 16.10. Italy
  • 16.11. Australia
  • 16.12. Brazil
  • 16.13. Spain
  • 16.14. Russia
  • 16.15. Mexico

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2025
  • 17.2. FPNV Positioning Matrix, 2025
  • 17.3. Market Concentration Analysis, 2025
    • 17.3.1. Concentration Ratio (CR)
    • 17.3.2. Herfindahl Hirschman Index (HHI)
  • 17.4. Recent Developments & Impact Analysis, 2025
  • 17.5. Product Portfolio Analysis, 2025
  • 17.6. Benchmarking Analysis, 2025

18. Company Profiles

  • 18.1. Thermo Fisher Scientific Inc.
  • 18.2. Lonza Group
  • 18.3. Catalent, Inc.
  • 18.4. Merck KGaA
  • 18.5. AGC Biologics
  • 18.6. Charles River Laboratories International, Inc.
  • 18.7. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
  • 18.8. Wuxi AppTec Co., Ltd.
  • 18.9. Oxford Biomedica PLC
  • 18.10. Revvity, Inc.
  • 18.11. Advanced BioScience Laboratories, Inc.
  • 18.12. Takara Bio Inc.
  • 18.13. MaxCyte, Inc.
  • 18.14. Genezen Laboratories, Inc.
  • 18.15. Batavia Biosciences B.V.
  • 18.16. Biovian Oy
  • 18.17. Boehringer Ingelheim International GmbH
  • 18.18. Creative Biogene
  • 18.19. Danaher Corporation
  • 18.20. FinVector Oy
  • 18.21. GE HealthCare Technologies, Inc.
  • 18.22. Miltenyi Biotec B.V. & Co. KG
  • 18.23. Novartis AG
  • 18.24. Sanofi SA
  • 18.25. SK pharmteco Inc.
  • 18.26. uniQure N.V.
  • 18.27. VGXI Inc.
  • 18.28. Waisman Biomanufacturing

LIST OF FIGURES

  • FIGURE 1. GLOBAL VIRAL VECTOR MANUFACTURING MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL VIRAL VECTOR MANUFACTURING MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL VIRAL VECTOR MANUFACTURING MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL VIRAL VECTOR MANUFACTURING MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 27. GLOBAL VIRAL VECTOR MANUFACTURING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ADENOVIRAL VECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ADENOVIRAL VECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ADENOVIRAL VECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL LENTIVIRAL VECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL LENTIVIRAL VECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL LENTIVIRAL VECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL RETROVIRUS VECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL RETROVIRUS VECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL RETROVIRUS VECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GAMMA-RETROVIRUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GAMMA-RETROVIRUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GAMMA-RETROVIRUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ALPHA-RETROVIRUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ALPHA-RETROVIRUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ALPHA-RETROVIRUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ADENO-ASSOCIATED VIRUS (AAV) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ADENO-ASSOCIATED VIRUS (AAV) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ADENO-ASSOCIATED VIRUS (AAV) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SINGLE-STRANDED AAV MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SINGLE-STRANDED AAV MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SINGLE-STRANDED AAV MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SELF-COMPLEMENTARY AAV MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SELF-COMPLEMENTARY AAV MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SELF-COMPLEMENTARY AAV MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HERPES SIMPLEX VECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HERPES SIMPLEX VECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HERPES SIMPLEX VECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DOWNSTREAM PROCESSING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DOWNSTREAM PROCESSING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DOWNSTREAM PROCESSING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL VECTOR DESIGN & CLONING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL VECTOR DESIGN & CLONING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL VECTOR DESIGN & CLONING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TRANSFECTION/TRANSDUCTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TRANSFECTION/TRANSDUCTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TRANSFECTION/TRANSDUCTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL UPSTREAM PROCESSING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL UPSTREAM PROCESSING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL UPSTREAM PROCESSING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PURIFICATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PURIFICATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PURIFICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CONCENTRATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CONCENTRATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CONCENTRATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL FORMULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL FORMULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL FORMULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL EX VIVO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL EX VIVO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL EX VIVO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL IN VIVO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL IN VIVO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL IN VIVO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL RESEARCH-SCALE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL RESEARCH-SCALE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL RESEARCH-SCALE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PRECLINICAL/PROCESS DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PRECLINICAL/PROCESS DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PRECLINICAL/PROCESS DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CLINICAL-SCALE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CLINICAL-SCALE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CLINICAL-SCALE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL COMMERCIAL-SCALE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL COMMERCIAL-SCALE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL COMMERCIAL-SCALE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL RARE GENETIC DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL RARE GENETIC DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL RARE GENETIC DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEUROLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NEUROLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEUROLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CENTRAL NERVOUS SYSTEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CENTRAL NERVOUS SYSTEM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CENTRAL NERVOUS SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PERIPHERAL NERVOUS SYSTEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PERIPHERAL NERVOUS SYSTEM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PERIPHERAL NERVOUS SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL OPHTHALMOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL OPHTHALMOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL OPHTHALMOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL IMMUNOLOGY & INFLAMMATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL IMMUNOLOGY & INFLAMMATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL IMMUNOLOGY & INFLAMMATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CARDIOVASCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CARDIOVASCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CARDIOVASCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL METABOLIC & ENDOCRINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL METABOLIC & ENDOCRINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL METABOLIC & ENDOCRINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL AUTOLOGOUS THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL AUTOLOGOUS THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL AUTOLOGOUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ALLOGENEIC THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ALLOGENEIC THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ALLOGENEIC THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL VACCINOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL VACCINOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL VACCINOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL RESEARCH & DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL RESEARCH & DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL RESEARCH & DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL ACADEMIC & RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL ACADEMIC & RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL ACADEMIC & RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL ACADEMIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL ACADEMIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL ACADEMIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL GOVERNMENT LABS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL GOVERNMENT LABS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL GOVERNMENT LABS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE VIRAL VECTOR MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RETROVIRUS VECTORS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV), 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE VIRAL VECTOR MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE VIRAL VECTOR MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE VIRAL VECTOR MANUFACTURING MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RETROVIRUS VECTORS, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV), 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RETROVIRUS VECTORS, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV), 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RETROVIRUS VECTORS, 2018-2032 (USD MILLION)
  • TABLE 194. LATIN AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV), 2018-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 196. LATIN AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST VIRAL VECTOR MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RETROVIRUS VECTORS, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV), 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST VIRAL VECTOR MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST VIRAL VECTOR MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST VIRAL VECTOR MANUFACTURING MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RETROVIRUS VECTORS, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV), 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 236. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 237. NATO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 238. NATO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. NATO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RETROVIRUS VECTORS, 2018-2032 (USD MILLION)
  • TABLE 240. NATO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV), 2018-2032 (USD MILLION)
  • TABLE 241. NATO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 242. NATO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 243. NATO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 244. NATO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 245. NATO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 246. NATO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 247. NATO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 248. NATO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 249. NATO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 250. NATO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 251. NATO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 252. G7 VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 253. G7 VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. G7 VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RETROVIRUS VECTORS, 2018-2032 (USD MILLION)
  • TABLE 255. G7 VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV), 2018-2032 (USD MILLION)
  • TABLE 256. G7 VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 257. G7 VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 258. G7 VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 259. G7 VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 260. G7 VIRAL VECTOR MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 261. G7 VIRAL VECTOR MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 262. G7 VIRAL VECTOR MANUFACTURING MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 263. G7 VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 264. G7 VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 265. G7 VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 266. G7 VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RETROVIRUS VECTORS, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV), 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPEAN UNION VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION VIRAL VECTOR MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPEAN UNION VIRAL VECTOR MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION VIRAL VECTOR MANUFACTURING MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPEAN UNION VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPEAN UNION VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RETROVIRUS VECTORS, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV), 2018-2032 (USD MILLION)
  • TABLE 286. BRICS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 287. BRICS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 288. BRICS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 289. BRICS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 290. BRICS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 291. BRICS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 292. BRICS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 293. BRICS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 294. BRICS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 295. BRICS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 296. BRICS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 297. ASEAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 298. ASEAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. ASEAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RETROVIRUS VECTORS, 2018-2032 (USD MILLION)
  • TABLE 300. ASEAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV), 2018-2032 (USD MILLION)
  • TABLE 301. ASEAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 302. ASEAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 303. ASEAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 304. ASEAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 305. ASEAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 306. ASEAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 307. ASEAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 308. ASEAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 309. ASEAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 310. ASEAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 311. ASEAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 312. GCC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 313. GCC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 314. GCC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RETROVIRUS VECTORS, 2018-2032 (USD MILLION)
  • TABLE 315. GCC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV), 2018-2032 (USD MILLION)
  • TABLE 316. GCC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 317. GCC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 318. GCC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 319. GCC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 320. GCC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 321. GCC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 322. GCC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 323. GCC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 324. GCC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 325. GCC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 326. GCC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 327. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 328. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 329. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 330. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RETROVIRUS VECTORS, 2018-2032 (USD MILLION)
  • TABLE 331. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV), 2018-2032 (USD MILLION)
  • TABLE 332. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 333. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 334. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 335. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 336. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 337. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 338. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 339. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 340. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZ